California upstart Xyphos wants to tackle CAR-T’s big problems – Endpoints News
Endpoints News |
California upstart Xyphos wants to tackle CAR–T's big problems
Endpoints News If, however, the cancer patient begins experiencing toxicity, the doctor could stop the antibody therapy. The antibody then cycles out of the patient, and the CARs revert to harmless, inactive T cells. Its sort of like switching T cells on and off when … AvidBiotics Splits into Two Biotechnology Companies Each Developing its Distinct Technology Platform |
